NASDAQ:SGMT Sagimet Biosciences Q4 2024 Earnings Report $7.10 +0.42 (+6.29%) Closing price 04:00 PM EasternExtended Trading$7.02 -0.09 (-1.20%) As of 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Sagimet Biosciences EPS ResultsActual EPS-$0.50Consensus EPS -$0.65Beat/MissBeat by +$0.15One Year Ago EPSN/ASagimet Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASagimet Biosciences Announcement DetailsQuarterQ4 2024Date3/12/2025TimeBefore Market OpensConference Call DateWednesday, March 12, 2025Conference Call Time7:30AM ETUpcoming EarningsSagimet Biosciences' Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, August 11, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Sagimet Biosciences Earnings HeadlinesSagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)1 hour ago | globenewswire.comSagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Rating of "Moderate Buy" from BrokeragesJune 16, 2026 | americanbankingnews.comBlackRock's CEO is calling this "the next major evolution"Larry Fink, CEO of BlackRock - the world's largest asset manager with $10 trillion under management - is calling this 'the next major evolution in market infrastructure.' He's referring to a complete overhaul of America's financial system, and by law the entire $382 trillion U.S. financial system must migrate onto it by April 2027. BlackRock launched a fund on this new infrastructure and hit $2.8 billion in assets in three months. JPMorgan is running $2 billion a day through it. Goldman Sachs, Citi, Bank of America, and Wells Fargo have all announced full integration. The digital fuel powering this grid is up 374% over the last five years.June 22 at 1:00 AM | Awesomely, LLC (Ad)Sagimet Biosciences (NASDAQ:SGMT) Shares Down 0.2% - Here's What HappenedJune 16, 2026 | americanbankingnews.comSagimet Biosciences Announces Board Changes and Director ElectionsJune 12, 2026 | tipranks.comSagimet Biosciences Grants New Performance-Based Executive Equity AwardsJune 3, 2026 | tipranks.comSee More Sagimet Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sagimet Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sagimet Biosciences and other key companies, straight to your email. Email Address About Sagimet BiosciencesSagimet Biosciences (NASDAQ:SGMT) (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis. In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes. The company’s research platform leverages a proprietary chemokine-targeted approach to address underlying disease mechanisms rather than solely treating symptoms. By focusing on the molecular cues that recruit pro-fibrotic cells, Sagimet aims to develop therapies with the potential for disease modification in conditions that today have limited treatment options. Headquartered in the San Francisco Bay Area, Sagimet Biosciences operates research and development facilities that support both in-house discovery and collaborative initiatives with academic and industry partners. Since its formation in 2020, the company has built a team of scientists and clinicians with expertise in fibrosis biology, protein engineering and translational medicine. This multidisciplinary organization is structured to accelerate candidates from early discovery through proof-of-concept studies. Sagimet’s leadership team is led by President and Chief Executive Officer Dr. Steven Landis, a recognized expert in fibrotic disease research and a co-founder of the company’s predecessor, Cirius Therapeutics. Under Dr. Landis’s guidance, Sagimet has established a clear clinical development plan for CM-101 and is advancing strategic collaborations to expand its pipeline. The company’s strategic vision is centered on delivering first-in-class and best-in-class therapies for patients with high-unmet-need fibrotic disorders.View Sagimet Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Buy CrowdStrike Before the Stock Split? Here's the CaseUSA Today's Digital Revival Is Gaining Steam, But With Plenty of RiskBurlington Is Winning Over Shoppers But Investors Need PatienceInvestors Are Buying Into Sweetgreen Again—Should They?Cheesecake Factory Stock Is Up Over 50%—Is There Room for More CAKE?3 Oil Refiners Built to Cash In on Higher Crack SpreadsSatellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Upcoming Earnings FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
